Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombin and its pharmacologic regulation]

M C Guillin1

  • 1Service d'Hématologie et Immunologie, CHU Xavier Bichat, Paris.

Presse Medicale (Paris, France : 1983)
|October 10, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A critical role for Gly25 in the B chain of human thrombin.

Journal of thrombosis and haemostasis : JTH·2005
Same author

Antiphospholipid antibodies and the coagulation cascade.

Rheumatic diseases clinics of North America·2001
Same author

Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.

Gastroenterology·2001
Same author

Factor V Leiden related Budd-Chiari syndrome.

Gut·2001
Same author

Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.

Hepatology (Baltimore, Md.)·2000
Same author

A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood.

British journal of haematology·1999
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Thrombin is a key enzyme in clot formation, activating platelets and fibrinogen. New direct thrombin inhibitors are being developed to overcome limitations of heparin therapy, especially in cases of heparin-induced thrombocytopenia.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Context:

  • Thrombin is a critical enzyme in hemostasis and thrombosis, regulating clot formation by converting fibrinogen to fibrin and activating platelets.
  • Cellular interactions involving thrombin are mediated by protease-activated receptors (PARs), primarily PAR-1 and PAR-3.
  • Thrombin's structure, a serine protease with distinct active site grooves and exosites, dictates its substrate specificity and interactions.

Purpose:

  • To explore the multifaceted roles of thrombin in thrombus formation, inflammation, and wound repair.
  • To investigate the mechanism of action of heparin as an anticoagulant and its limitations.
  • To review the development and potential of direct thrombin inhibitors as alternatives to heparin therapy.

Summary:

Related Experiment Videos

  • Heparin exerts its antithrombotic effect by catalyzing the inhibition of thrombin by antithrombin III (AT), but this action is concentration-dependent and less effective on thrombin bound within a thrombus.
  • Heparin can also cause heparin-induced thrombocytopenia, a rare but serious complication, necessitating the exploration of alternative anticoagulants.
  • Direct thrombin inhibitors, targeting the enzyme's active site, are under investigation, with hirudin showing promise due to its broad inhibitory action and lack of cross-reactivity with heparin.

    • Impact:

    • Understanding thrombin's function is crucial for developing effective antithrombotic therapies.
    • The limitations of heparin highlight the need for safer and more versatile anticoagulants.
    • Direct thrombin inhibitors, particularly hirudin, represent a promising avenue for managing thrombotic disorders and preventing complications like heparin-induced thrombocytopenia.